LitCovid-sentences  

PMC:7200337 / 84379-87514 JSONTXT 11 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T481 0-36 Sentence denotes Corticosteroids for COVID-19 Therapy
T482 37-156 Sentence denotes Because of their anti-inflammatory activity, corticosteroids (CSs) are an adjuvant therapy for ARDS and cytokine storm.
T483 157-334 Sentence denotes However, the broad immunosuppression mediated by CS does raise the possibility that treatment could interfere with the development of a proper immune response against the virus.
T484 335-507 Sentence denotes A meta-analysis of 5,270 patients with MERS-CoV, SARS-CoV-1, or SARS-CoV-2 infection found that CS treatment was associated with higher mortality rate (Yang et al., 2020c).
T485 508-725 Sentence denotes A more recent meta-analysis of only SARS-CoV-2 infection assessed 2,636 patients and found no mortality difference associated with CS treatment, including in a subset of patients with ARDS (Gangopadhyay et al., 2020).
T486 726-873 Sentence denotes Other studies have reported associations with delayed viral clearance and increased complications in SARS and MERS patients (Sanders et al., 2020).
T487 874-1038 Sentence denotes In fact, the interim guidelines updated by the WHO on March 13, 2020 advise against giving systemic corticosteroids for COVID-19 (World Health Organization, 2020a).
T488 1039-1083 Sentence denotes Yet, new data from COVID-19 are conflicting.
T489 1084-1302 Sentence denotes One group reported no significant difference in time to viral clearance between patients who received methylprednisolone orally (mild disease) or intravenously (i.v.) (severe) and those who did not (Fang et al., 2020).
T490 1303-1564 Sentence denotes Retrospective studies from groups in China report that patients who were transferred to the ICU were less likely to have received CSs (Wang et al., 2020b) and that patients with ARDS who received methylprednisolone had reduced mortality risk (Wu et al., 2020a).
T491 1565-1809 Sentence denotes In contrast, another retrospective analysis found that patients who received CSs were more likely to have either been admitted to the ICU or perished, although the CS-treated group also had significantly more comorbidities (Wang et al., 2020c).
T492 1810-2002 Sentence denotes A smaller observational study of 31 patients found no association between corticosteroid treatment and time to viral clearance, length of hospital stay, or symptom duration (Zha et al., 2020).
T493 2003-2246 Sentence denotes A larger study of adjuvant CSs in 244 patients with critical COVID-19 found no association with 28-day mortality; subgroup analysis of patients with ARDS found no association between treatment with CSs and clinical outcomes (Lu et al., 2020b).
T494 2247-2344 Sentence denotes They also found that increased dosage was significantly associated with increased mortality risk.
T495 2345-2600 Sentence denotes A retrospective review of 46 patients, of whom 26 received i.v. methylprednisolone, found that early, low-dose administration significantly improved SpO2 and chest CT, time to fever resolution, and time on supplemental oxygen therapy (Wang et al., 2020h).
T496 2601-2788 Sentence denotes Others have published perspectives in support of early (Lee et al., 2020) and short-term, low-dose administration (Shang et al., 2020) based on anecdotal evidence but not clinical trials.
T497 2789-2935 Sentence denotes Most of the current data on CS use in COVID-19 are from observational studies and support either modest clinical benefit or no meaningful effects.
T498 2936-3135 Sentence denotes Larger RCTs are necessary to understand the risks and benefits of CSs for these patients; there are 22 trials evaluating various corticosteroids registered on ClinicalTrials.gov as of April 27, 2020.